COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS

摘要

597915 Disclosed is the use of an antagonist antibody to IL-23, or an antigen binding fragment thereof in the manufacture of a medicament for treating a subject having cancer or exhibiting a flare up of an autoimmune disease, wherein the medicament is for use in a dosage regimen comprising: a) administration of the medicament in a series of one or more doses over a first time interval; and b) administration of an acute phase therapeutic agent comprising an antagonist antibody or antigen binding fragment thereof that specifically binds to a cytokine or a receptor for a cytokine, selected from the group consisting of IL-1, TNF-?, IL-17A, and IL-17F in a series of one or more doses over a second time interval, wherein the second time interval (i) begins before or at the same time the first time interval begins and (ii) ends before the first time interval ends.